Agreement will enhance BenchSci's vast biomedical database to help scientists run more successful experiments while increasing discoverability of Taylor & Francis Group research

KND Biopharma is an enterprise-level supplier and best-in-class producer of hemp-derived Active Pharmaceutical Ingredients (API)

The addition of Gino Santini, Bob Yedid, and Joe Petko Significantly Expands Company's Pharmaceutical and Financial Markets Experience and Capabilities

New research collaboration and licensing agreement with Lacerta provides UCB access to a novel gene therapy program and proprietary AAV capsids

New digital image analysis data of stained tissues and biopsies with FibroNest is presented for the continuous assessment of the severity and regression of Fibrosis in human in-vitro 3D NASH Spheroid models and for the automated classification of post-transplant patients in F4 Fibrosis Stage with and without Hepatocellular carcinoma (HCC) at the Liver Meeting Digital Experience 2020

Aalto Bio Reagents Launches First Monoclonal Antibody Against SARS-CoV-2 Nucleocapsid Protein.

Where tactical precision, creative thinking, expert analysis, and passion provide quality outcomes.

Enalare Therapeutics Inc., a clinical stage biopharmaceutical company dedicated to developing and commercializing novel therapies for patients suffering from acute respiratory conditions, announced today that it has appointed biopharma industry veteran Herm Cukier as its Executive Chairman of the Board, President, and Chief Executive Officer.

The newest product in Hardy Diagnostics' line of chromogenic, selective and differential culture media

5th Annual Massachusetts Manufacturer of the Year

Congresswoman Donna Shalala to join leading scientists, developers, regulators, and policy/business decision-makers who are seeking to accelerate translation of major scientific discoveries into products that slow the aging process and onset of major chronic diseases.

(i) Study shows Philogen's proprietary immunocytokines are effective treatment for brain tumors.
(ii) Early promising findings from Philogen's Phase I/II study investigating the safety and efficacy of L19TNF monotherapy in patients with glioblastoma.
(iii) Philogen's proprietary cancer treatment found to be safe and well-tolerated.

This marks the 11th U.S. provisional patent application filed by GBS covering the use of CCCM™ for unique medical disorders, creating an IP portfolio that contains formulas for up to 50 potential therapeutic indications.

COVID-19 is highlighting the U.S.' reliance on foreign pharmaceuticals: CapsCanada® presents solutions to the situation